"Dopamine Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
| Descriptor ID |
D018492
|
| MeSH Number(s) |
D27.505.519.625.150.175 D27.505.696.577.150.175
|
| Concept/Terms |
Dopamine Antagonists- Dopamine Antagonists
- Dopaminergic Antagonists
- Dopamine Blockers
- Blockers, Dopamine
- Antagonists, Dopamine Receptor
- Receptor Antagonists, Dopamine
- Antagonists, Dopaminergic
- Dopamine Receptor Antagonists
- Antagonists, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Antagonists".
This graph shows the total number of publications written about "Dopamine Antagonists" by people in this website by year, and whether "Dopamine Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Antagonists" by people in Profiles.
-
Kremens DE. Treatment Strategies for Tardive Dyskinesia. J Clin Psychiatry. 2019 12 24; 81(1).
-
Ruzek M, Richman P, Eskin B, Allegra JR. ED treatment of migraine patients has changed. Am J Emerg Med. 2019 Jun; 37(6):1069-1072.
-
Dusitanond P, Young WB. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem. 2009 Mar; 9(1):63-70.
-
Agovic MS, Yablonsky-Alter E, Lidsky TI, Banerjee SP. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10; 587(1-3):181-6.
-
Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y, Alexander M, Rohde CA, Syversen T, Decamp E, Koser AJ, Fritz S, Gonczi H, Anderson DW, Schneider JS. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol. 2006 Dec; 202(2):381-90.
-
Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, Moore H, Kandel ER. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006 Feb 16; 49(4):603-15.
-
Young WB, Piovesan EJ, Biglan KM. Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr. 2003 Jun; 8(6):450-6.
-
Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial. Neurology. 2003 Jan 28; 60(2):315-21.
-
Richman PB, Reischel U, Ostrow A, Irving C, Ritter A, Allegra J, Eskin B, Szucs P, Nashed AH. Droperidol for acute migraine headache. Am J Emerg Med. 1999 Jul; 17(4):398-400.
-
Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP. Antipsychotic drug effects on glutamatergic activity. Brain Res. 1997 Aug 01; 764(1-2):46-52.